Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Spritzler

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2002
Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantationLeonard H Calabrese, Michael M Lederman, John Spritzler, et al.
The Journal of Infectious Diseases|May 4, 2004
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment responseDonna Mildvan, Ronald J Bosch, Ryung S Kim, et al.
AIDS (London, England)|September 20, 2013
Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reductionRobert C Kalayjian, John Spritzler, Roy M Matining, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384Rajesh T Gandhi, John Spritzler, Ellen Chan, et al.
Plos One|April 6, 2012
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialJonathan Z Li, Chanson J Brumme, Michael M Lederman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivityTimothy J Wilkin, Mathew Bidwell Goetz, Robert Leduc, et al.
The Journal of Infectious Diseases|July 29, 2010
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core proteinRobert T Schooley, John Spritzler, Hongying Wang, et al.
The Journal of Infectious Diseases|March 16, 2011
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trialJonathan Z Li, Zabrina L Brumme, Chanson J Brumme, et al.
AIDS Research and Human Retroviruses|February 13, 2002
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV diseaseAlan L Landay, Daniel Bettendorf, Ellen Chan, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2002
Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantationLeonard H Calabrese, Michael M Lederman, John Spritzler, et al.
The Journal of Infectious Diseases|May 4, 2004
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment responseDonna Mildvan, Ronald J Bosch, Ryung S Kim, et al.
AIDS (London, England)|September 20, 2013
Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reductionRobert C Kalayjian, John Spritzler, Roy M Matining, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 1, 2006
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384Rajesh T Gandhi, John Spritzler, Ellen Chan, et al.
Plos One|April 6, 2012
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialJonathan Z Li, Chanson J Brumme, Michael M Lederman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivityTimothy J Wilkin, Mathew Bidwell Goetz, Robert Leduc, et al.
The Journal of Infectious Diseases|July 29, 2010
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core proteinRobert T Schooley, John Spritzler, Hongying Wang, et al.
The Journal of Infectious Diseases|March 16, 2011
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trialJonathan Z Li, Zabrina L Brumme, Chanson J Brumme, et al.
AIDS Research and Human Retroviruses|February 13, 2002
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV diseaseAlan L Landay, Daniel Bettendorf, Ellen Chan, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
Pageof 3